Healthpia America is a Palisades Park, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
GTESS Corporation is a Richardson, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Rothenberger USA is a Rockford, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Mountain Health Network is a West Virginia-based not-for-profit health delivery system comprised of Cabell Huntington Hospital, a 303-bed teaching hospital for Marshall University Schools of Medicine, Pharmacy and Nursing; St. Mary`s Medical Center, a 393-bed teaching hospital that operates St. Mary`s Schools of Nursing, Respiratory Care and Medical Imaging; Hoops Family Children`s Hospital, a 72-bed pediatric specialty hospital within Cabell Huntington Hospital; HIMG, a 60-member multi-specialty physician group; and a management agreement with Pleasant Valley Hospital, a 101 acute-bed hospital. Mountain Health is committed to improving the health and well-being of over one million children and adults in 23 counties in West Virginia, southern Ohio, and eastern Kentucky through understanding, respecting, and meeting their needs.
Enterin is pioneering the medical community`s understanding of the link between infections, dysfunction of the enteric nervous system (ENS) of the gut, and the early onset and chronic progression of neurodegenerative disease. We are leveraging years of research to become the first company in the world to develop a novel drug that repairs the dysfunctional gut-brain axis in patients with neurodegenerative disease. Our lead compound, ENT-01 (also known as kenterin), displaces membrane-bound alpha- synuclein (αS) aggregates from nerve cells in the ENS and improves neural signaling between the gut and the brain in preclinical models of Parkinson`s disease. In the gut, this results in improved motility. We are now progressing this drug through clinical trials in an attempt to reverse the constipation of Parkinson`s disease. Our long-term mission is to become the world leader in developing pharmaceutical therapies that repair the gut-brain axis.